Related Experiment Video
Updated: Mar 10, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T Williamson1,2, Rowan Miller1,2, Helen N Pemberton1,2
1The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK.
Abstract:
Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in ARID1A represent one of the most common molecular alterations in human cancer, but therapeutic approaches that target these defects are not yet clinically available. We demonstrate that defects in ARID1A sensitize tumour cells to clinical inhibitors of the DNA damage checkpoint kinase, ATR, both in vitro and in vivo. Mechanistically, ARID1A deficiency results in topoisomerase 2A and cell cycle defects, which cause an increased reliance on ATR checkpoint activity. In ARID1A mutant tumour cells, inhibition of ATR triggers premature mitotic entry, genomic instability and apoptosis. The data presented here provide the pre-clinical and mechanistic rationale for assessing ARID1A defects as a biomarker of single-agent ATR inhibitor response and represents a novel synthetic lethal approach to targeting tumour cells.
Insights
Defects in ARID1A mutations sensitize cancer cells to ATR inhibitors, offering a new synthetic lethal strategy. This research identifies ARID1A as a potential biomarker for ATR inhibitor response in targeted cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Identifying genetic biomarkers for synthetic lethality is crucial for developing targeted cancer therapies.
- ARID1A mutations are common in human cancers, yet targeted treatments are lacking.
- Synthetic lethality exploits genetic defects to selectively kill cancer cells.
Purpose of the Study:
- To investigate the therapeutic potential of targeting ARID1A-deficient tumors.
- To explore the synthetic lethal interaction between ARID1A defects and ATR inhibitors.
- To establish ARID1A as a predictive biomarker for ATR inhibitor sensitivity.
Main Methods:
- In vitro and in vivo studies using ARID1A-deficient tumor models.
- Assessment of tumor cell sensitivity to ATR inhibitors.
- Mechanistic investigation of ARID1A deficiency effects on DNA damage response and cell cycle.
- Evaluation of ATR inhibition-induced apoptosis and genomic instability.
Main Results:
- ARID1A-deficient tumor cells exhibit increased sensitivity to ATR inhibitors.
- ARID1A deficiency leads to topoisomerase 2A and cell cycle defects, increasing reliance on ATR.
- ATR inhibition in ARID1A mutant cells causes premature mitotic entry, genomic instability, and apoptosis.
- Pre-clinical data support ARID1A as a biomarker for ATR inhibitor response.
Conclusions:
- ARID1A defects represent a novel synthetic lethal vulnerability exploitable by ATR inhibitors.
- Targeting ATR in ARID1A-mutant cancers offers a promising therapeutic strategy.
- ARID1A serves as a predictive biomarker for single-agent ATR inhibitor therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy